E.g., 06/04/2023
E.g., 06/04/2023

NEPHROCHECK® Biomarkers TIMP-2 and IGFBP7 Included in the ERAS “Guidelines for Perioperative Care in Cardiac Surgery”

15 May, 2019

“Global-PPS”, a survey of antibiotic use and bacterial resistance in hospitals worldwide, tops the 200,000 patients

15 April, 2019

Baxter and bioMérieux announce collaboration to improve identification and treatment of acute kidney injury

19 March, 2019

bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking

13 November, 2018

bioMérieux acquires a majority stake in Hybiome and strengthens its presence both in China and in the immunoassay market

09 November, 2018

NEPHROCHECK Biomarkers TIMP-2 and IGFBP7 Included in Groundbreaking Consensus Statement of Best Practices to Enhance Recovery after Heart Surgery

02 May, 2018

bioMérieux and the University of Antwerp award scholarships to three healthcare professionals for their commitment to improve antibiotic use in order to combat antimicrobial resistance

23 April, 2018

bioMérieux submits for FDA Clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel

19 April, 2018

bioMérieux reinforces its offering of High Medical Value immunoassay biomarkers with the acquisition of Astute Medical

05 April, 2018

Marcy l’Étoile, France – April 4th, 2018 – bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis of high-risk medical conditions and diseases through the identification and validation of protein biomarkers. In particular, Astute developed the NEPHROCHECK® test, an FDA-cleared test for the early risk assessment of acute kidney injuries (AKI) based on the level of two biomarkers, IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7) and TIMP-2 (Tissue Inhibitor Metalloproteinases-2).

bioMérieux receives FDA clearance for expanded pathogen identification capability on VITEK® MS

31 July, 2017

With more than 15,000 distinct strains, VITEK® MS provides the microbiology lab with the most comprehensive Mass Spectrometry database to improve clinical decision-making for infectious diseases 

Pioneering diagnostics